Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, Phase II Trial to Evaluate the Efficacy of Ivonescimab, a PD 1/VEGF Bispecific Antibody, Versus FOLFOX as Second Line Therapy for Locally Advanced/Metastatic Biliary Cancers

NCT06529718 is registered in ClinicalTrials.gov with UNICANCER as lead sponsor.

NCT NCT06529718
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06529718 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, Phase II Trial to Evaluate the Efficacy of Ivonescimab, a PD 1/VEGF Bispecific Antibody, Versus FOLFOX as Second Line Therapy for Locally Advanced/Metastatic Biliary Cancers
Lead sponsor
UNICANCER
Phase
Phase 2
Overall status
Recruiting
Start date
October 9, 2025
Completion date
January 30, 2029
Enrollment
72 (estimated)
Sites
42

Conditions

As the registry lists them; a condition with its own page is linked.

biliary tract cancer